EntryPoint Capital LLC Makes New $210,000 Investment in Lantheus Holdings, Inc. (NASDAQ:LNTH)

EntryPoint Capital LLC bought a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 4th quarter, Holdings Channel.com reports. The institutional investor bought 2,344 shares of the medical equipment provider’s stock, valued at approximately $210,000.

Several other large investors have also made changes to their positions in LNTH. Janus Henderson Group PLC boosted its position in Lantheus by 7.7% in the third quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider’s stock valued at $393,844,000 after buying an additional 257,022 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Lantheus by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock worth $184,798,000 after acquiring an additional 32,551 shares in the last quarter. Reinhart Partners LLC. grew its position in Lantheus by 9.9% during the 4th quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider’s stock worth $122,280,000 after acquiring an additional 123,282 shares during the last quarter. Swedbank AB increased its holdings in Lantheus by 53.3% during the 4th quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock valued at $99,054,000 after purchasing an additional 385,000 shares in the last quarter. Finally, Portolan Capital Management LLC raised its position in Lantheus by 6.1% in the 3rd quarter. Portolan Capital Management LLC now owns 670,881 shares of the medical equipment provider’s stock valued at $73,629,000 after purchasing an additional 38,776 shares during the last quarter. Institutional investors own 99.06% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Robert J. Jr. Marshall sold 10,000 shares of the company’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares in the company, valued at $11,445,207.20. This represents a 8.07 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Mary Anne Heino sold 53,107 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares of the company’s stock, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 64,109 shares of company stock worth $6,110,806. Insiders own 1.50% of the company’s stock.

Lantheus Price Performance

LNTH opened at $96.16 on Friday. The firm has a 50 day simple moving average of $93.21 and a 200 day simple moving average of $96.42. Lantheus Holdings, Inc. has a fifty-two week low of $58.16 and a fifty-two week high of $126.89. The company has a market cap of $6.59 billion, a price-to-earnings ratio of 16.00 and a beta of 0.38.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. As a group, analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. The Goldman Sachs Group began coverage on Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price on the stock. B. Riley lowered their price objective on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research report on Friday, March 21st. JMP Securities reiterated a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a research report on Tuesday, January 14th. Finally, Truist Financial increased their price target on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $129.43.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.